Sponsor Oversight
Elevating your trials by Seamless Execution, Compliance, and Data Integrity with our Sponsor Oversight mechanism
Elevating your trials by Seamless Execution, Compliance, and Data Integrity with our Sponsor Oversight mechanism
The sponsor holds sole accountability for management and monitoring of clinical trials. Therefore, there should be systems in place to ensure that contracted or outsourced tasks are being closely monitored guaranteeing patient wellbeing and data integrity.
USFDA has recommended the “Guidance for Industry Oversight of Clinical Investigations – — A Risk-Based Approach to Monitoring”emphasizing the importance of effective monitoring to protect human subjects and ensure high-quality studies. Sponsors of clinical investigations involving human drugs are required to provide oversight to ensure the rights, welfare, and safety of subjects and the quality of clinical trial data submitted to the FDA.
As per ICH E6 R2, the sponsor may establish an independent data monitoring committee (IDMC) to assess the progress of a clinical trial, including safety data and critical efficacy endpoints. The IDMC should have written operating procedures and maintain records of meetings. The sponsor should ensure oversight of trial-related duties and functions carried out on its behalf, including those subcontracted to another party by the sponsor’s contracted CRO(s).
Adherence to GCP is crucial and should be prioritized over internal policies and procedures. The contract should address subcontracting and outline the sponsor’s oversight of additional subcontracting. However, key legislative requirements, such as reporting urgent safety measures and serious breaches, are often missing from contracts, potentially leading to non-compliance due to unclear roles and responsibilities.
Zenovel maintains the highest standards for safeguarding patients and ensuring data authenticity through comprehensive supervision procedures, guaranteeing efficient management and monitoring of clinical studies.
The European Union’s Good Manufacturing Practice (GMP) standards, as outlined in the Annex to the Guide to Good Manufacturing Practice for Medicinal Products, ensure the quality and safety of medicinal products, including those used in clinical trials. The Qualified Person (QP) plays a crucial role in batch certification, particularly for
In the intricate process of developing new pharmaceuticals, guaranteeing product safety, effectiveness, and adherence to global regulations is essential. Batch release testing acts as a pivotal quality assurance measure, confirming that medications comply with rigorous criteria before distribution. When combined with International Council for Harmonisation (ICH) standards, this testing framework
In the world of life sciences, quality isn’t just a benchmark—it’s the backbone of success. Three key pillars—Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Laboratory Practice (GLP)—form the core framework that supports everything from product development to regulatory approval. These standards aren’t just industry buzzwords; they’re the
In the pharmaceutical industry, quality is paramount—and at Zenovel, we are deeply committed to delivering excellence in Quality Assurance (QA). Our focus is on ensuring that every medicine is developed, manufactured, and delivered with safety and reliability as top priorities. QA is embedded in every stage of the pharmaceutical lifecycle—from
The U.S. Food and Drug Administration (FDA) emphasize the importance of data integrity in pharmaceutical manufacturing, particularly under its Current Good Manufacturing Practices (CGMP) rules. However, issues like fake lab results and sloppy record-keeping persist, posing risks to patients and losing confidence in the system. Independent oversight is crucial to
In the rapidly evolving pharmaceutical industry, assuring product quality and customer safety is a need. This endeavour continues to be based on validation, a methodical procedure to verify that manufacturing procedures and equipment consistently deliver high-quality outcomes. A strong strategy to validation is required in 2025 due to the complexity
